JNJ

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over.

After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help bring an end to litigation that has dogged ​the company for over a decade.

Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer.

Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.

Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, caused ovarian cancer, with the company committing up to $5.5 billion to settle the remaining claims. The proposed resolution would bring an end to a long-running legal battle that has involved around 76,000 ovarian talc claims and weighed on the healthcare company for more than a decade.

Johnson & Johnson (NYSE:JNJ)  was last seen up 2.4% at $272.31, and earlier hit a record high of $274.90, after the healthcare giant agreed to pay $5.5 billion to settle roughly 76,000 remaining U.S. lawsuits alleging its talc products caused ovarian cancer.

Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer.

J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.

The 2026 Social Security COLA came in at just 2.8%, which is barely keeping pace with a grocery bill, let alone replacing a paycheck.

Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.